JAK1 and rheumatoid arthritis: Recently, tofacitinib, a potent and selective JAK inhibitor, with a functional selectivity for signalling pathways mediated by JAK-1 heterodimers (JAK-1/3, JAK-1/2, JAK-1/Tyk-2), showed a good safety profile and efficacy on RA [14–17].